We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Analysts Expect Surge in Parkinson's Disease Treatment Market

By LabMedica International staff writers
Posted on 12 Jul 2015
Print article
The market for drugs to treat Parkinson's disease is expected to grow dramatically over the next several years, driven primarily by an aging population and increasing disease prevalence.

Three new drugs are expected to lead the surge of newly approved drugs and drug candidates. These include Rytary, manufactured by Impax (Hayward, CA, USA), which was approved by the US Food and Drug Administration (FDA) in January 2015; safinamide (Xadago) from Newron Pharmaceuticals (Milan, Italy), which was approved in Europe in February 2015 and accepted for a New Drug Application by the FDA in March 2015; and CVT-301, which is being developed by Acorda (Ardsley, NY, USA).

Rytary is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Safinamide is a reversible and selective monoamine oxidase B inhibitor, reducing degradation of dopamine, and a glutamate release inhibitor. It also seems to inhibit dopamine reuptake. Additionally, safinamide blocks sodium and calcium channels.

CVT-301 is a self-administered, inhaled formulation of levodopa (L-dopa) in development for treatment of OFF episodes in Parkinson’s disease, and is being studied to provide rapid, reliable delivery of a precise dose of L-dopa through the lungs to return people with Parkinson’s to an ON state. OFF episodes, which increase in frequency and severity during the course of the disease, are defined by periods of time when background L-dopa therapy does not adequately control Parkinson’s symptoms.

The market analysis firm GlobalData (London, United Kingdom) estimated that the Parkinson’s disease treatment market value across the eight major countries of the USA, France, Germany, Italy, Spain, the United Kingdom, Japan, and Brazil will reach 4.7 billion USD by 2022.

GlobalData further predicted that global sales for safinamide and Rytary will reach 409.6 million USD and 202.2 million USD, respectively, by 2022. They also suggested that CVT-301 would garner strong sales of 458.6 million USD in 2022.

Related Links:

Impax
Newron Pharmaceuticals
Acorda


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.